Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott glucose meter

This article was originally published in The Gray Sheet

Executive Summary

Firm has received new reports of instances wherein its FreeStyle and FreeStyle Flash blood glucose meters in the U.S. "become inoperable or may revert to a reset condition," potentially leading to a change in the units of measurement and, consequently, misguiding therapy decisions. The July 20 announcement follows a related Class I recall in October 2005. Abbott has issued a letter to healthcare professionals and all customers potentially affected. Meanwhile, it reminds users to check each time they test to make sure the meter's display is correct. J&J/LifeScan has had similar issues with its OneTouch Ultra blood glucose meter (1"The Gray Sheet" Jan. 2, 2006, p. 5)...

You may also be interested in...



FDA Warning Letter Cites J&J Unit For Not Heeding “User Error” Complaints

Johnson & Johnson/LifeScan received a warning letter for neglecting to adequately follow up on frequent reports of user errors associated with its blood glucose meters

‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

HBW Market News: GNC US Chief, Clasado Commercial Head, Barentz Funding

GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.

UsernamePublicRestriction

Register

MT023786

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel